Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16F3NO |
Molecular Weight | 295.2995 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC[C@@H](OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2
InChI
InChIKey=WIQRCHMSJFFONW-OAHLLOKOSA-N
InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1279447Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15886723 | https://www.ncbi.nlm.nih.gov/pubmed/10208643 | https://www.ncbi.nlm.nih.gov/pubmed/8512621
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1279447
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15886723 | https://www.ncbi.nlm.nih.gov/pubmed/10208643 | https://www.ncbi.nlm.nih.gov/pubmed/8512621
(R)-Norfluoxetine is a pharmacologically active metabolite of Fluoxetine that is a selective serotonin reuptake inhibitor. (R)-Norfluoxetine was being investigated by Eli Lilly and Company for treatment pain and drug abuse, but future development was discontinued.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888 |
7490.0 nM [Ki] | ||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888 |
3661.0 nM [Ki] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888 |
26.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8512621
Rats were treated with Norfluoxetine (0-20mg/kg)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8512621
Rat cortical membranes equivalent to 50 mkg of protein were incubated at 37°C for 30 minutes in 2 ml of reaction medium containing the (R)-Norfluoxetine (1-1000nM), 0.1 nM [3Hlparoxetine, 50 mmol/L Tris-HG, pH 7.4, 150 mmol/L NaG, and 5 mmol/L KCl. Fluoxetine at 1 mkM/kg was used to determine nonspecific binding
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
130194-43-3
Created by
admin on Sat Dec 16 09:49:31 GMT 2023 , Edited by admin on Sat Dec 16 09:49:31 GMT 2023
|
PRIMARY | |||
|
9797657
Created by
admin on Sat Dec 16 09:49:31 GMT 2023 , Edited by admin on Sat Dec 16 09:49:31 GMT 2023
|
PRIMARY | |||
|
05UQ1299DN
Created by
admin on Sat Dec 16 09:49:31 GMT 2023 , Edited by admin on Sat Dec 16 09:49:31 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD